BioNTech is buying into one of the hottest areas of oncology, agreeing to pay $800 million to acquire China-based Biotheus ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

For Merck, the drug that concerns investors is Keytruda. The blockbuster cancer drug faces patent expiration in 2028.

Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...

Germany’s Bayer saw its shares tumble almost 11% to 21.76 euros this morning, as it reported level third-quarter 2024 sales ...

Amid fears of an "extremely high level of violent protests," the Brampton Triveni Mandir and Community Centre has cancelled a Life Certificate Event.

Phuket is pulling out all the stops in a monumental bid to raise a whopping 290 million baht. The cause? Building a cutting-edge cancer care centre at Vachira Phuket Hospital. This essential ...